Feasibility study of radium-223 production in Tehran Research Reactor for treatment of bone metastases

Bagheri, Reza; Afarideh, Hossein; Bahrami-Samani, Ali; Shirvani Arani, S.; Ghanadi Maraghe, Mohammad

Feasibility study of radium-223 production in Tehran Research Reactor for treatment of bone metastases

Document Type : Research Paper

Authors

Reza Bagheri

Hossein Afarideh

Ali Bahrami-Samani

S. Shirvani Arani

Mohammad Ghanadi Maraghe

Abstract

Bone metastasis is a major clinical concern that can cause severe pain, bone fractures, spinal cord compression, hypercalcemia and other problems for patients. Variuos β emitter radionuclides have been used for bone pain palliation, but recently α emitter radionucliedes also have shown acceptable results of treatment of bone metastasis. Radium-223 (t1/2=11.43 d) is one of the suitable α emitters that emits high energy α particles (Ēav=5.64 MeV) with high linear energy transfer (LET) that delivers a killing dose to the tumor cells. In this research, the feasibility of production of radium-223 from radium-226 was studied in Tehran Research Reactor (TRR) in thermal neutron flux of 4×1013 cm-2 s-1 using MATLAB software. Then, the data were compared with the experimental results. On average, over 80 percent agreement was observed between the calculated and experimental data, and under appropriate conditions the acceptable activity of 227Ac as a precursor of 223Ra was obtained. The results showed that with one month neutron bombardment of 2.5 mg 226Ra in TRR and cooling for 4 months, it is theoretically possible to achieve about 8.51 MBq (0.23 mCi) activity of 223Ra, that with respect to injection of about 3.7 MBq (0.1 mCi) per patient (with normally 70 kg weight), it is possible to administer the produced 223Ra to more than 2 patients in every equilibrium period.

Keywords

Bone metastasis

Radium-223

Tehran Research Reactor

[1] T. Guise, Examining the Metastatic Niche: Targeting the Microenvironmen, Semin Oncol 37 (Suppl 2) (2010) 2-14.

[2] A.N Serafini, Therapy of metastatic bone pain, J. Nucl Med, 42 (2001) 895-906.

[3] R.E. Coleman, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res, 12 (20 Pt 2) (2006) 6243-6249.

[4] J.A. Campa, R. Rayne, The management of intractable bone pain: a clinician’s perspective, Semin. Nucl. Med., 22 (1992) 3-10.

[5] W. Brenner, W.U. Kampen, A.M. Kampen, E. Henze, Skeletal Uptake and Soft-Tissue Retention of 186Re-HEDP and 153Sm EDTMP in Patients with Metastatic Bone Disease, J. Nucl Med, 42 (2001) 230-236.

[6] J.G. Rajendran, J.F. Eary, W. Bensinger, L.D. Durack, C. Vernon, A. Fritzberg, High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation, J. Nucl Med, 43 (2002) 1383-1390.

[7] S. Banerjee, 177Lu-DOTMP, 153Sm-DOTMP, 175Yb-EDTMP and 186/188Re-CTMP: Novel Agent for Bone Pain Palliation and their Comparison with 153Sm-EDTMP, Founder’s Day Special Issue, (2005).

[8] M.A. Ritter, J.E. Cleaver, C.A. Tobias, High-LET radiations induce a large proportion of non-rejoining DNA breaks, Nature, 266 (1977) 653-655.

[9] T. Ramdahl, R. Larsen, Targeted alpha emitters in tumor therapy, Drug Discovery & Development, IPT. 20 (2006) 36-38.

[10] S. Nilsson, R.H. Larsen, S.D. Fossa, L. Balteskard, K.W. Borch, J.E. Westlin, G. Salberg, O.S. Bruland, First Clinical Experience with α Emitting Radium-223 in the Treatment of Skeletal Metastases,” Clin Cancer Res, 1 (2005) 4451-4459.

[11] G. Pfennig, H.Klewe-Nebenius, W. Seelmann-Eggebert, KARLSRUHER NKLIDKARTE, 6th. Edition, Longman Press (1995).

[12] G. Henriksen, D.R. Fisher, J.C. Roeske, O.S. Bruland, R.H. Larsen, Targeting of Osseous Sites with α-Emitting 223Ra: Comparison with the α-Emitting 89Sr in Mice, J. Nucl Med, 44 (2003) 252-259.

[13] L.I. Guseva, N.N. Dogadkin, A tandem generator for production and isolation short-lived α-emitting radionuclides of Ra, Pb, and Bi in EDTA solutions, Radiochemistry, 50 (2008) 310-315.

[14] Z.K. Karalova, R.N. Ivanov, B.F. Myaseodov, L.M. Rodionova, Z.I. Pyzhova, S.M. Kalebin, V.Ya. Gabeskiriya, Production of 227Ac and 227Th isotopes by irradiation of radium in the SM-2 reactor, At Energ, 2 (1972) 119-122.
[15] Radium, Los Alamos National Laboratory, Retrieved on 2009-08-05.

[16] J.E. Martin, Physics for radiation protection, 2ed edition, WILEY-VCH Verlag GmbH & Co, KGaA, Weinheim (2006).

[17] R.A. Kuznetsov, P.S. Butkalyuk, V.A. Tarasov, A.Yu. Baranov, I.L. Butkalyak, E.G. Romanov, V.N. Kupriyanov, E.V. Kazakova, Yields of Activation Products in 226Ra Irradiation in the High-Flux SM Reactor, Radiochemistry, 54 (2012) 383-387.